Baseline was created as a daily supplement to naturally support the endocannabinoid system, which supports many vital functions in the body. *Each product within the line is designed to promote homeostasis through plant-based solutions and features a benefit-driven brand architecture that closely maps to the needs of today's hyper stimulated and overly stressed consumers.
Baseline's formulations include full-spectrum, hemp-derived CBD infused with whole plant ingredients and adaptogens. The Company believes these compounds in concert with the properties of CBD offer a unique and highly effective product.
"The market is excited about the potential of CBD, and for good reason," commented
- A Daily Supplementation Approach
Baseline formulations are designed for daily use to naturally supplement and provide cumulative benefits. The endocannabinoid system plays a key role in regulating basic functions like stress, mood, sleep, digestion, metabolism, immunity, and inflammatory response*. The Company believes that low-dose CBD products used consistently produce both immediate and cumulative results that can help regulate this system and keep this vast range of functions in equilibrium. Users are guided toward daily supplementation in the form of consistently dosed, easily portable capsules available through monthly subscription or single purchase.
- Need State Specific Formulations
CBD products are often marketed as a 'cure-all' to address a broad list of ailments or needs. Through querying various consumer segments, the Baseline team uncovered the four most common wellness-related issues, and developed formulations aimed at addressing those specific needs. Baseline is offered in four variations: Day Shift to promote energy,
- A Commitment to Bioavailability
Baseline products are created through an innovative process using proprietary dry liposome preparation in which liposomal technology is used to encapsulate active ingredients and increase bioavailability. By encapsulating hemp extract rich in terpenes and CBD into liposomes, this process significantly improves the absorption of terpenes and CBD into the intestinal cells and prolongs its effect in the body.**
Baseline products undergo rigorous in-house and independent third-party lab testing, with a Certificate of Analysis provided for each batch. Additionally, the products are non-GMO and GMP Certified.
Baseline is now available for purchase at baselinecbd.co.
*The Endocannabinoid System: An Overview
Direct link: www.frontiersin.org/articles/10.3389/fnbeh.2012.00009/full
**Liposomes as Advanced Delivery Systems for Nutraceuticals
Direct link: www.ncbi.nlm.nih.gov/pmc/articles/PMC4818067/
About International Cannabrands
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Disclaimer Concerning Forward-Looking Statements
Certain statements included herein constitute "forward-looking statements" relating to implied performance or acceptance of the products, within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Investors are cautioned not to put undue reliance on forward-looking statements. Additional risks and uncertainties regarding the Company are described in its publicly-available disclosure documents filed by the Company on SEDAR (www.sedar.com). The forward-looking statements contained in this news release represent the Company's expectations as of the date of this news release, or as of the date they are otherwise stated to be made, and subsequent events may cause these expectations to change. Except as required by law, the Company does not intend, and undertakes no obligation to update any forward-looking statements to reflect, in particular, new information or future events.
International Cannabrands Contact:
Chief Executive Officer,
Ph: +1-(323) 828-4321
steve.gormley@intlcannabrands.com
Investor Relations Contact:
Vice President,
#350, 318 - 11
Ph: +1-(403) 221-0915
dave@howardgroupinc.com
Media Inquiries: media@intlcannabrands.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/international-cannabrands-announces-the-official-launch-of-baseline-cbd-301007262.html
SOURCE
© Canada Newswire, source